The MTRX K1

An advanced touchless technology that scans a person's physiology to analyze their health in seconds to identify and prevent disease transmission.

Dr. Andrew Huff, Co-Founder, CEO

There is no effective affordable, rapid, and scalable infectious disease surveillance platform to rapidly identify and communicate infectious disease outbreaks globally. Once novel infectious disease transmission begins locally, it often takes months to develop laboratory based diagnostic tests and vast resources to scale and deploy globally. As we saw with COVID-19, by the time that laboratory tests have been developed it is often too late to prevent global disease spread. Once laboratory tests are developed they are often too expensive for small businesses or resource poor communities to obtain. Once sustained disease transmission occurs, there are no effective solutions to rapidly screen people for infectious diseases and organizations often resort to using ineffective health screening technologies like temperature checks and questionnaires to mitigate disease spread. This is highly problematic because most people that have an infectious disease do not have a fever. For example, fewer than 44% of people with COVID-19 experience a fever. This leaves humanity with few effective and scalable options to identify infectious diseases early, or to prevent sustained disease transmission in the community.

The target audience of our technology is businesses, governments, and private organizations. As our technology advances, we are reducing the size of the K1 and reducing the cost of the K1 so that we deploy as many of these devices as we can globally. When our technology is deployed the information that we collect democratizes infectious disease surveillance and benefits the entire global population by preventing the spread  of infectious diseases. We are meeting with leaders of private organizations and government bodies on a daily basis to determine how we can provide value to them. We have also been speaking with the people that use our technology at these organizations to perpetually improve the system. We financially incentivize current users of our products to provide us with feedback and our technical field staff routinely collects data and information from our users (employees, patients, and everyday people that visit locations with K1s). We are attempting to revolutionize the infectious disease surveillance and healthcare paradigms. To successfully do this we have to provide value to both the organization that purchases or funds the technology, and to the people being scanned, beyond the COVID-19 pandemic.

• We are disrupting the medical device market by providing an equitable health scanning solution to millions of people at no cost to the end users
  • In contrast, wearable health monitoring devices are expensive, create e-waste, are expensive, and are not equitable to the poor

• Our solution helps identify infectious disease outbreaks faster than any other existing technology in the world and helps prevent pandemics

• Once a disease is spreading in the community, our solution helps prevent local and community infectious disease transmission; thereby, shortening recovery time and reduces the duration of the outbreak, epidemic, or pandemic

• Via our API, our solution helps organizations globally share and analyze de-identified health scan data and this democratizes biosurveillance
  

• Our solution changes the healthcare treatment paradigm by making health scanning an everyday part of life (instead of only collecting physiological data, at the doctor's office, when a person is ill)
  • This could save millions of lives and forever change healthcare
  • In the future, this will be a huge benefit to our end users because we might be able to provide early detection of other serious medical conditions

• We have automated the first steps of healthcare, and provide value beyond COVID-19

Our solution is tangible and is concrete. Every person that is scanned by the MTRX K1 benefits from having their physiology measured in precise detail (4.5 million measurements in 9 seconds). There is no fee or cost for anyone to use the device, a person simply approaches the device, stands still for 9 seconds while being scanned and the result is instantly generated. The largest customers in our sales pipeline are assisted living facilities and large urban healthcare centers. The elderly and urban populations are most vulnerable to, or at risk of, infectious diseases like COVID-19. After testing our devices at our customers' facilities we have entered negotiations for large sales of our product. Additionally, having a rapid low cost health scanning technology benefits everyone globally when infectious disease outbreaks are identified early, it helps prevent the outbreaks from turning into epidemics or pandemics, which saves the world trillions of dollars and saves millions of lives. Additionally, our technology automates the first steps of healthcare which provides value beyond COVID, and increases the likelihood that our technology will continue to be adopted after the pandemic. As mentioned previously, our technology has been tested extensively.

The first steps to validate our business to our partners, was to prove to Extreme Networks and Microsoft that we could scale our operations. We can scale manufacturing to 500,000 units per, over the course of 2 years. We have secured the necessary supplier agreements with our raw materials and component suppliers, and our Tier 1 and 2 manufacturers.

We have designed all of our software to be scalable to reduce costs and increase efficiency. We have partnered with both Microsoft and Extreme Networks to help scale the sales and marketing of our products globally.

We are also in the process of designing a low-cost and smaller version of the K1, which will likely have greater market penetration in low income communities, small businesses, and the developing world.

We have formed an advisory board that meets quarterly to review progress and discuss corporate strategy. The executive team meets weekly and discusses daily key performance metrics.

We measure impact by evaluating:

1. the amount of devices being used
2. the amount of people using the devices
3. the amount of scans per device
4. the amount of scans per person per day
5. the amount of alerts or notification generated
6. the geographic distribution of the previously statistics
7. the geographic areas or regions being served globally
8. the feedback from our customers or end users

All of the devices that we have sold are being used by our customers, and they have reported overwhelmingly positive feedback which has resulted in additional sales of the product and referrals to their partners. We are averaging 8,000 daily scans, with 1.2 scans per person per day. This represents an average of 250 scans per day per device, with a positive rate of 1/100 scans on average. Users are located in California, Ontario, Michigan, New York, Mississippi, Ohio, Florida, and Illinois.

The biggest barrier to accomplishing our goals is educating the consumers and end users on our product. Since our technology is so revolutionary, it is very difficult to have someone understand how it works. Since the majority of the population is conditioned to believe that the only way to measure physiology is with a physical device attached to someone's body, many people have a very difficult time understanding or believing that physiology can be measured with electromagnetic energy. To overcome this barrier, we continually have to educate the customers and users of our product.

Another barrier, is the cost of the current version of our product. The current cost is $10,000 per K1. While the cost per person scan is fractions of a cent for the lifetime of the device, this initial cost is too much to bear for some customers. To help our customers with the cost we have created financing programs with JP Morgan Chase and have leasing options available. Ideally, we want to improve our design and engineering to reduce our costs and pass these savings on to the customer so that our system will have maximum market penetration globally.

Extreme Networks

Microsoft

Alunos

Panasonic

The biggest barrier that we have is time. We need to move quickly and  need to have our team's time completely dedicated to the project. Currently, we cannot afford to pay our staff as full time employees. The co-founders (working full time since inception) and executive team believe so strongly in what we are doing that we have not paid ourselves anything, and have dumped every single dollar into product research and development and scaling. Receiving this funding will guarantee the success of our technology and will help us change biosurveillance, healthcare, and mitigate pandemics before they occur.

We would like to partner with many of your organizations.

Here is a list of who and why:

• Aviva - the data that we collect can reduce health insurance costs and will help us grow in their market
• Bill & Melinda Gates Foundation - can help bring our solution to poor nations and under-served populationsBrunswick - can help our company navigate complex multi-organizational partnerships and data sharing agreements
• Discovery - the data that we collect can reduce health insurance costs and will help us enter a new market
• Optum - the data that we collect can reduce health insurance costs and help their patients identify an illness before it becomes a clinical visit
• Patrick McGovern - we could potentially collaborate on refining our health scanning ML algorithms
• Internews - can help communicate our products availability and value to end users in resource poor locations globally
• Reckitt - we can provide technology to help them with their re-entry hygiene solutions
• Tencent - Can help us market and communicate our technology in Asian markets